Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) FCF Margin (2020 - 2025)

Ovid Therapeutics filings provide 6 years of FCF Margin readings, the most recent being 1444.85% for Q4 2025.

  • Quarterly FCF Margin rose 1168936.0% to 1444.85% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 588.58% through Mar 2026, up 846634.0% year-over-year, with the annual reading at 528.13% for FY2025, 937399.0% up from the prior year.
  • FCF Margin hit 1444.85% in Q4 2025 for Ovid Therapeutics, up from 9751.52% in the prior quarter.
  • Across five years, FCF Margin topped out at 77.21% in Q1 2021 and bottomed at 106664.32% in Q3 2022.
  • Average FCF Margin over 5 years is 15198.17%, with a median of 8928.43% recorded in 2023.
  • Peak annual rise in FCF Margin hit 9751845bps in 2023, while the deepest fall reached -1613754bps in 2023.
  • Ovid Therapeutics' FCF Margin stood at 77.21% in 2021, then tumbled by -28501bps to 21929.06% in 2022, then skyrocketed by 62bps to 8397.18% in 2023, then plummeted by -56bps to 13134.21% in 2024, then soared by 89bps to 1444.85% in 2025.
  • Per Business Quant, the three most recent readings for OVID's FCF Margin are 1444.85% (Q4 2025), 9751.52% (Q3 2025), and 76.12% (Q2 2025).